Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 312 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR “The power of science”: HPV vaccine proven to dramatically reduce cervical... November 3, 2021 2026 ESMO TAT Honorary Award Recipient Announced February 3, 2026 FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia November 3, 2021 Financial Navigation Can Reduce the Financial Toxicity of Cancer Care April 21, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Generic Eribulin Antibody Drug Ejects Problematic Proteins from Cancer Cells Research with integrity – why colour blindness is a research integrity... Study in India Could Make Immunotherapy More Affordable Worldwide
